ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

izalontamab brengitecan

Also written as “BL-B01D1”, “Iza-bren” and “BMS-986507”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Small Cell Lung Carcinoma · Triple Negative Breast Neoplasms · Breast Neoplasms · Carcinoma, Transitional Cell, led by 2 companies.

Drug pageIzalontamab brengitecan: every studyAll 59 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 25, 202355 company-led studies, 55 open or runningLicense: SystImmune (Biokin) → Bristol Myers Squibb, Dec 2023Next primary completion: Nov 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sichuan Biokin Pharmaceuticalits history only5050 open or runningphase 3since Oct 25, 2023Jan 4, 2022Nov 2026phase 3 · NCT06118333
Bristol-Myers Squibb55 open or runningphase 3since Apr 8, 2025Sep 26, 2024Mar 13, 2028phase 3 · NCT06926868
  • Named in Bristol-Myers Squibb’s own pipeline as iza-bren, phase 3, as of Oct 29, 2026 (source).

Also a collaborator on its studies: Baili-Bio (Chengdu) Pharmaceutical.

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of Bristol-Myers Squibb only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Aug 6, 2023Named izalontamab brengitecanINNProposed as its International Nonproprietary Name in WHO's List 129 · before, BMS-986507
  2. Dec 11, 2023Bristol Myers Squibb licensed it from SystImmune (Biokin)LicenseOutside mainland China, developed and sold jointly in the US · announced · SystImmune and Bristol Myers Squibb (release)
  3. Sep 26, 2024First study: phase 2 study in Lung NeoplasmsFirst studyNCT06618287 · 416 planned · United States, Australia, Canada and more
  4. Apr 8, 2025Phase 3 study in Breast NeoplasmsNCT06926868 · 600 planned · United States, Argentina, Australia and more
  5. Jul 31, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07100080 · 661 planned · United States, Argentina, Belgium and more
  6. Aug 5, 2025Phase 3 study in Urinary Bladder NeoplasmsNCT07106762 · 470 planned · United States, Argentina, Australia and more
  7. Jun 26, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07680790 · 850 planned · United States, Argentina, Australia and more

Ahead

  1. Mar 13, 2028Primary completion: phase 3 study in Breast NeoplasmsNCT06926868
  2. Dec 15, 2028Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT07100080
  3. Jan 26, 2029Primary completion: phase 3 study in Urinary Bladder NeoplasmsNCT07106762
  4. Feb 26, 2031Primary completion: phase 2 study in Lung NeoplasmsNCT06618287

TargetBeta

“A dual-targeted antibody-drug conjugate (ADC) consisting of a bispecific antibody directed against both the epidermal growth factor receptor (EGFR; HER1; ErbB1) and the epidermal growth factor receptor 3 (HER3; ErbB3) conjugated, via a cathepsin-B cleavable linker, to the camptothecin derivative …”NCIt, read by Claude
“A dual-targeted antibody-drug conjugate (ADC) consisting of a bispecific antibody directed against both the epidermal growth factor receptor (EGFR; HER1; ErbB1) and the epidermal growth factor receptor 3 (HER3; ErbB3) ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
Anti-EGFR/Anti-HER3 Bispecific Antibody-drug Conjugate AVZO-1418ruleavenzo-therapeutics-incphase 21
CS5007ruleCStone Pharmaceuticalsphase 11

Studies

All 5 Bristol-Myers Squibb leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07680790Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3RecruitingDec 30, 2031850
NCT07106762Urinary Bladder Neoplasms · United States, Argentina, Australia and more3RecruitingJan 26, 2029470
NCT07100080Carcinoma, Non-Small-Cell Lung · United States, Argentina, Belgium and more3RecruitingDec 15, 2028661
NCT06926868Breast Neoplasms · United States, Argentina, Australia and more3RecruitingMar 13, 2028600
NCT06618287Lung Neoplasms · United States, Australia, Canada and more2RecruitingFeb 26, 2031416

How it is read

Names in the registry

  • “BL-B01D1”, 49 entries
  • “Iza-bren”, 4 entries
  • “BMS-986507”, 1 entry
  • “BL-B01D1 for Injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.